L García-Álvarez1, J R Caso2, M P García-Portilla3, L de la Fuente-Tomás1, L González-Blanco4, P Sáiz Martínez5, J C Leza2, J Bobes5. 1. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Área de Psiquiatría, Facultad de Medicina, Universidad de Oviedo, Spain; Instituto de Neurociencias del Principado de Asturias (INEUROPA), Spain. 2. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Departamento de Farmacología, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Instituto Universitario de Investigación en Neuroquímica UCM, Madrid, Spain. 3. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Área de Psiquiatría, Facultad de Medicina, Universidad de Oviedo, Spain; Instituto de Neurociencias del Principado de Asturias (INEUROPA), Spain; Servicio de Salud del Principado de Asturias, SESPA, Spain. Electronic address: albert@uniovi.es. 4. Área de Psiquiatría, Facultad de Medicina, Universidad de Oviedo, Spain; Servicio de Salud del Principado de Asturias, SESPA, Spain. 5. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Área de Psiquiatría, Facultad de Medicina, Universidad de Oviedo, Spain; Instituto de Neurociencias del Principado de Asturias (INEUROPA), Spain; Servicio de Salud del Principado de Asturias, SESPA, Spain.
Abstract
BACKGROUND: Immune-inflammatory processes have been implicated in schizophrenia (SCH), but their specificity is not clear. MAIN AIM: To identify potential differential intra-/intercellular biochemical pathways controlling immune-inflammatory response and their oxidative-nitrosative impact on SCH patients, compared with bipolar disorder (BD) patients and healthy controls (HC). METHODS: Cross-sectional, naturalistic study of a cohort of SCH patients (n=123) and their controls [BD (n=102) and HC (n=80)]. STATISTICAL ANALYSIS: ANCOVA (or Quade test) controlling for age and gender when comparing the three groups, and controlling for age, gender, length of illness, cigarettes per day, and body mass index (BMI) when comparing SCH and BD. RESULTS: Pro-inflammatory biomarkers: Expression of COX-1 was statistically higher in SCH and BD than HC (P<0.0001; P<0.0001); NFκB and PGE2 were statistically higher in SCH compared with BD (P=0.001; P<0.0001) and HC (P=0.003; P<0.0001); NLRP3 was higher in BD than HC (P=0.005); and CPR showed a gradient among the three groups. Anti-inflammatory biomarkers: BD patients had lower PPARγ and higher 15d-PGJ2 levels than SCH (P=0.005; P=0.008) and HC (P=0.001; P=0.001). Differences between SCH and BD: previous markers of SCH (NFκB and PGE2) and BD (PPARγ and 15d-PGJ2) remained statistically significant and, interestingly, iNOS and COX-2 (pro-inflammatory biomarkers) levels were statistically higher in SCH than BD (P=0.019; P=0.040). CONCLUSIONS: This study suggests a specific immune-inflammatory biomarker pattern for established SCH (NFκB, PGE2, iNOS, and COX-2) that differentiates it from BD and HC. In future, their pharmacological modulation may constitute a promising therapeutic target.
BACKGROUND: Immune-inflammatory processes have been implicated in schizophrenia (SCH), but their specificity is not clear. MAIN AIM: To identify potential differential intra-/intercellular biochemical pathways controlling immune-inflammatory response and their oxidative-nitrosative impact on SCH patients, compared with bipolar disorder (BD) patients and healthy controls (HC). METHODS: Cross-sectional, naturalistic study of a cohort of SCH patients (n=123) and their controls [BD (n=102) and HC (n=80)]. STATISTICAL ANALYSIS: ANCOVA (or Quade test) controlling for age and gender when comparing the three groups, and controlling for age, gender, length of illness, cigarettes per day, and body mass index (BMI) when comparing SCH and BD. RESULTS: Pro-inflammatory biomarkers: Expression of COX-1 was statistically higher in SCH and BD than HC (P<0.0001; P<0.0001); NFκB and PGE2 were statistically higher in SCH compared with BD (P=0.001; P<0.0001) and HC (P=0.003; P<0.0001); NLRP3 was higher in BD than HC (P=0.005); and CPR showed a gradient among the three groups. Anti-inflammatory biomarkers: BD patients had lower PPARγ and higher 15d-PGJ2 levels than SCH (P=0.005; P=0.008) and HC (P=0.001; P=0.001). Differences between SCH and BD: previous markers of SCH (NFκB and PGE2) and BD (PPARγ and 15d-PGJ2) remained statistically significant and, interestingly, iNOS and COX-2 (pro-inflammatory biomarkers) levels were statistically higher in SCH than BD (P=0.019; P=0.040). CONCLUSIONS: This study suggests a specific immune-inflammatory biomarker pattern for established SCH (NFκB, PGE2, iNOS, and COX-2) that differentiates it from BD and HC. In future, their pharmacological modulation may constitute a promising therapeutic target.
Authors: Xinyang Zhou; Shehan M Fernando; Alexander Y Pan; Rebecca Laposa; Kathryn R Cullen; Bonnie Klimes-Dougan; Ana C Andreazza Journal: Int J Mol Sci Date: 2021-11-19 Impact factor: 5.923
Authors: Clara Martínez-Cao; Lorena de la Fuente-Tomás; Ainoa García-Fernández; Leticia González-Blanco; Pilar A Sáiz; María Paz Garcia-Portilla; Julio Bobes Journal: Transl Psychiatry Date: 2022-05-11 Impact factor: 7.989
Authors: Marta Garés-Caballer; Joan Vicent Sánchez-Ortí; Patricia Correa-Ghisays; Vicent Balanzá-Martínez; Gabriel Selva-Vera; Joan Vila-Francés; Rafael Magdalena-Benedito; Constanza San-Martin; Victor M Victor; Irene Escribano-Lopez; Antonio Hernandez-Mijares; Juliana Vivas-Lalinde; Eduard Vieta; Juan C Leza; Rafael Tabarés-Seisdedos Journal: Front Neurol Date: 2022-06-02 Impact factor: 4.086
Authors: Ángela Velasco; Julia Rodríguez-Revuelta; Emilie Olié; Iciar Abad; Abel Fernández-Peláez; Aurélie Cazals; Sébastien Guillaume; Lorena de la Fuente-Tomás; Luis Jiménez-Treviño; Laura Gutiérrez; Paz García-Portilla; Julio Bobes; Philippe Courtet; Pilar A Sáiz Journal: Eur Psychiatry Date: 2020-02-17 Impact factor: 5.361